Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative befotertinib in resectable EGFR-mutant NSCLC
ChiCTR2400084057Phase 2Recruiting
- Sponsor
- Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of befotertinib in non-small cell lung cancer (NSCLC), sponsored by Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University. Primary endpoints: Incidence of complications and Major pathologic response. Started May 2024; status: recruiting.
02
Drugs
befotertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400084057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084057.